"This is the worst possible outcome for Amgen."
-Barclays analyst Emily Field, on Novartis announcing a disappointing result for its heart disease drug, a disclsoure that also cast doubt on one of Amgen's big drugs.
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
September 08, 2026 17:30 ET (21:30 GMT)